[go: up one dir, main page]

WO2008135259A3 - Antibody molecule composition - Google Patents

Antibody molecule composition Download PDF

Info

Publication number
WO2008135259A3
WO2008135259A3 PCT/EP2008/003586 EP2008003586W WO2008135259A3 WO 2008135259 A3 WO2008135259 A3 WO 2008135259A3 EP 2008003586 W EP2008003586 W EP 2008003586W WO 2008135259 A3 WO2008135259 A3 WO 2008135259A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody molecule
molecule composition
heavy chain
light chain
variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/003586
Other languages
French (fr)
Other versions
WO2008135259A2 (en
Inventor
Steffen Goletz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycotope GmbH
Original Assignee
Glycotope GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope GmbH filed Critical Glycotope GmbH
Publication of WO2008135259A2 publication Critical patent/WO2008135259A2/en
Publication of WO2008135259A3 publication Critical patent/WO2008135259A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Antibody comprising at least a variable heavy chain and variable light chain, whereby the variable heavy chain is: QVQLKQSG PGLVQPSQSLS ITCTVSGFSLTNYGVHWVRQS PGKGLEWLGVIWS GGNTDYN TPFTSRLSiNKDNSKSQVFFKMNSLQSH Γ;TAI Y YCARALT YYDYEFAYWGQGTLVTVSTA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMI SRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 7YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQ QGNVFSCSVMHEGLHNHYTQKSLSLSPGK and/or the variable light chain is: DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTKGSPRLLIKYASESISGIPS RFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFI FPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
PCT/EP2008/003586 2007-05-04 2008-05-05 Antibody molecule composition Ceased WO2008135259A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07090094.9 2007-05-04
EP07090094 2007-05-04

Publications (2)

Publication Number Publication Date
WO2008135259A2 WO2008135259A2 (en) 2008-11-13
WO2008135259A3 true WO2008135259A3 (en) 2009-04-09

Family

ID=39944059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/003586 Ceased WO2008135259A2 (en) 2007-05-04 2008-05-05 Antibody molecule composition

Country Status (1)

Country Link
WO (1) WO2008135259A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3110447T3 (en) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Anti-egfr antibody and uses of same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085474A2 (en) * 2003-03-20 2004-10-07 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005080585A1 (en) * 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085474A2 (en) * 2003-03-20 2004-10-07 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005080585A1 (en) * 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QIAN ET AL: "Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC. NEW YORK, vol. 364, no. 1, 31 March 2007 (2007-03-31), pages 8 - 18, XP022005960, ISSN: 0003-2697 *

Also Published As

Publication number Publication date
WO2008135259A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
IL212100A0 (en) Cross-species-specific spcaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-irxcd3 or fapalphaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
WO2006105062A3 (en) Altered antibody fc regions and uses thereof
WO2009158071A3 (en) Solid support with a grafted chain
WO2008121616A3 (en) Antibodies with decreased deamidation profiles
WO2007115265A3 (en) Reagents useful for synthesizing rhodamine-labeled oligonucleotides
GB2428450B (en) Opposed piston engine with variable timing
WO2008002893A8 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2008024505A3 (en) Orbital engine
WO2008157109A3 (en) Turbocharger bypass valving
WO2008010837A3 (en) Noncompetitive immunoassays to detect small molecules
WO2008135259A3 (en) Antibody molecule composition
WO2008014313A3 (en) A process for forming perfluorinated-alkyl sulfonamide substituted norbornene-type monomers
AU2004901470A0 (en) Hydraulic pump .. with other uses
AU2006902470A0 (en) The town planner ref to PL 2002, No 2005901084, PL 1996
GB0600991D0 (en) Assays, antibodies and uses thereof
GB0508701D0 (en) Assays, antibodies and uses thereof
GB0521718D0 (en) Assays, antibodies and uses thereof
AU2005901102A0 (en) The I.D. charm
HK1158670A (en) Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
AU2005904463A0 (en) A Crankshaft Speed Variator
GB0516933D0 (en) Double seal, with fillter grip papers
HK1118778A (en) Spill resistant closure
HK1107134A (en) Two stroke steam-to-vacuum engine
AU2005100925A4 (en) The Rats Last Run
AU2005902300A0 (en) Closure with scavenger structure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08758383

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08758383

Country of ref document: EP

Kind code of ref document: A2